Wall Street ends 2026 positively with tech stocks dominating, but concerns over valuations drive interest in smaller AI ...

Patronus AI unveiled “Generative Simulators,” adaptive “practice worlds” that replace static benchmarks with dynamic reinforcement-learning environments to train more reliable AI agents for complex, ...

"We've worked on TPUs since 2014 ... a long time before AI was fashionable," Thomas Kurian said at the Fortune Brainstorm AI ...

Summary In this episode of The Defenders Log, Paul Mockapetris, the architect of DNS, discusses the evolving role of the Domain Name System from a simple directory to a sophisticated security tool. He ...

Nvidia's restraint — focusing on enabling the ecosystem rather than owning it — has helped cement its role as the ...

In this Monday edition of quantum computing news, we look at a new push by SEALSQ ($LAES) to build silicon-based quantum systems, Xanadu’s early ...

Eli Lilly is a well-established pharmaceutical company with a portfolio of products that consistently generate revenue and ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

At CES 2026, Nvidia unveiled a suite of AI innovations spanning data center, enterprise, robotics, and autonomous vehicles.

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Ahead of the MTG Lorwyn Eclipsed January 2026 launch, Wizards of the Coast revealed a wealth of cards that players can expect ...